Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study

by Jacques Medioni, Mara Brizard, Reza Elaidi, Paul F. Reid, Khadija Benlhassan, Dorothy Bray
Published 2017-09-01

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

by Reza Elaidi, Letuan Phan, Delphine Borchiellini, Philippe Barthelemy, Alain Ravaud, Stéphane Oudard, Yann Vano
Published 2020-06-01

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients.

by Yann-Alexandre Vano, Stéphane Oudard, Marie-Agnès By, Pauline Têtu, Constance Thibault, Hail Aboudagga, Florian Scotté, Reza Elaidi
Published 2018-01-01

Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression

by Ivan Pourmir, Reza Elaidi, Zineb Maaradji, Hortense De Saint Basile, Monivann Ung, Mohammed Ismaili, Laure Fournier, Bastien Rance, Laure Gibault, Rym Ben Dhiab, Benoit Gazeau, Elizabeth Fabre
Published 2023-11-01

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?

by Yann-Alexandre Vano, Sylvain Ladoire, Réza Elaidi, Slimane Dermeche, Jean-Christophe Eymard, Sabrina Falkowski, Marine Gross-Goupil, Gabriel Malouf, Bérangère Narciso, Christophe Sajous, Sophie Tartas, Eric Voog, Alain Ravaud
Published 2021-11-01